Legrand Competitors and Similar CompaniesClear all
Legrand's competitors and similar companies include Catalent, PPD, Catalent Pharma Solutions and WuXi Biologics.
 Legrand Legrand is a company that develops, produces, and sells pharmaceutical products and services. |  Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. |  PPD PPD (Pharmaceutical Product Development) is a company that provides drug development and laboratory solutions. |  Catalent Pharma Solutions Catalent Pharma Solutions is a company that provides drug delivery technologies and manufactures solutions for drugs, protein, cell, and gene therapy biologics, and consumer health products. |  WuXi Biologics WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development. | |
Founding Date | Founding Date 1986 | Founding Date 2007 | Founding Date 1985 | Founding Date 1989 | Founding Date 2010 |
Type | Type Private | Type Subsidiary | Type Subsidiary | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Bogotá, CO HQ | Locations Bridgewater, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations Wilmington, US HQ Buenos Aires, AR Melbourne, AU Brussels, BE Zaventem, BE São Paulo, BR São Paulo, BR see more | Locations Somerset, US HQ | Locations Wuxi, CN HQ George Town, KY Wuppertal, DE Hong Kong, HK Dundalk, IE Cranbury, US King Of Prussia, US |
Employees | Employees 3223% increase | Employees 12,6955% increase | Employees 24,5842% decrease | Employees 8,300 | Employees 12,575 |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $4.4b (FY, 2024) | Revenue (est.) $4.7b (FY, 2020) | Revenue (est.) N/A | Revenue (est.) ¥21.8b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $3.4b (FY, 2024) | Cost of goods $1.7b (FY, 2020) | Cost of goods N/A | Cost of goods ¥10b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $953m (FY, 2024) | Gross profit $3b (FY, 2020) | Gross profit N/A | Gross profit ¥12b (FY, 2025) |
Net income | Net income N/A | Net income ($1b) (FY, 2024) | Net income $160.6m (FY, 2020) | Net income N/A | Net income ¥5.7b (FY, 2025) |
Operating ⚠ | |||||
Backlog | Backlog N/A | Backlog $2.5b (FY, 2023) | Backlog $9.5b (Q3, 2021) | Backlog N/A | Backlog $18.5b (H1, 2022) |
Countries | Countries N/A | Countries 80 (FY, 2023) | Countries 46 (FY, 2020) | Countries N/A | Countries N/A |
For sources of this data, please see the company profile
View Company Profiles
Catalent
HQ
Bridgewater, US
Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products.
View companyPPD
HQ
Wilmington, US
PPD (Pharmaceutical Product Development) is a company that provides drug development and laboratory solutions.
View companyCatalent Pharma Solutions
HQ
Somerset, US
Catalent Pharma Solutions is a company that provides drug delivery technologies and manufactures solutions for drugs, protein, cell, and gene therapy biologics, and consumer health products.
View companyWuXi Biologics
HQ
Wuxi, CN
Employees
12,575
WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development.
View company